Search research articles
Contact Us
Filters
Showing results (301-310 of 316) with videos related to
Page
of 32
Sort By:
Acta Dermato-Venereologica
|
April 15, 2026
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)
Elena Pezzolo, Rossi Mariateresa, Raul Armando Luyo Saboya, et al.
Journal of the American Academy of Dermatology
|
January 10, 2024
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study
Gianluca Avallone, Luca Mastorino, Gianluca Tavoletti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 13, 2022
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis
Luca Stingeni, Leonardo Bianchi, Elettra Antonelli, et al.
The Journal of Dermatological Treatment
|
October 10, 2024
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis)
Luigi Gargiulo, Luciano Ibba, Angela Alfano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V Conteduca, D Wetterskog, M T A Sharabiani, et al.
Dermatology and Therapy
|
July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)
Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Clinical and Experimental Dermatology
|
June 11, 2025
Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched Study
Francesca Barei, Alessandra Chiei-Gallo, Alessandra Narcisi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 29, 2024
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study
Gianluca Avallone, Francesco Cavallo, Annalisa Tancredi, et al.
Clinical and Experimental Dermatology
|
July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo Nodularis
Gianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
Dermatology and Therapy
|
October 10, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study
Gianluca Avallone, Andrea Bombelli, Luigi Gargiulo, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 316) with videos related to
Sort By:
Page
of 32
Acta Dermato-Venereologica
|
April 15, 2026
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)
Elena Pezzolo, Rossi Mariateresa, Raul Armando Luyo Saboya, et al.
Journal of the American Academy of Dermatology
|
January 10, 2024
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study
Gianluca Avallone, Luca Mastorino, Gianluca Tavoletti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 13, 2022
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis
Luca Stingeni, Leonardo Bianchi, Elettra Antonelli, et al.
The Journal of Dermatological Treatment
|
October 10, 2024
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis)
Luigi Gargiulo, Luciano Ibba, Angela Alfano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V Conteduca, D Wetterskog, M T A Sharabiani, et al.
Dermatology and Therapy
|
July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)
Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Clinical and Experimental Dermatology
|
June 11, 2025
Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched Study
Francesca Barei, Alessandra Chiei-Gallo, Alessandra Narcisi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 29, 2024
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study
Gianluca Avallone, Francesco Cavallo, Annalisa Tancredi, et al.
Clinical and Experimental Dermatology
|
July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo Nodularis
Gianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
Dermatology and Therapy
|
October 10, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study
Gianluca Avallone, Andrea Bombelli, Luigi Gargiulo, et al.
Page
of 32